Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.
Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used for treatment of febrile neutropenia in systemic lupus erythematosus (SLE) and other systemic rheumatic diseases. We describe 2 patients with SLE with disease flares with irreversible loss of renal function in association with G-CSF therapy. Eighteen patients with SLE treated with G-CSF for neutropenia have been reported, of whom 4 developed mild disease flares or cutaneous vasculitis. Our experience suggests that G-CSF therapy should be used with considerable caution in patients with SLE.
Vasiliu
Irene M
IM
Department of Medicine, State University of New York at Buffalo, New York, USA.
Petri
Michelle A
MA
Baer
Alan N
AN
D000328:Adult; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000517:prevention & control; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D011994:Recombinant Proteins; D012008:Recurrence; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000517:prevention & control; D016896:Treatment Outcome; D014657:Vasculitis / Q000139:chemically induced* / Q000517:prevention & control
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor